Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 11

1.

A novel form of 4-1BBL has better immunomodulatory activity than an agonistic anti-4-1BB Ab without Ab-associated severe toxicity.

Schabowsky RH, Elpek KG, Madireddi S, Sharma RK, Yolcu ES, Bandura-Morgan L, Miller R, MacLeod KJ, Mittler RS, Shirwan H.

Vaccine. 2009 Dec 11;28(2):512-22. doi: 10.1016/j.vaccine.2009.09.127. Epub 2009 Oct 29.

2.

Immune regulation by 4-1BB and 4-1BBL: complexities and challenges.

Wang C, Lin GH, McPherson AJ, Watts TH.

Immunol Rev. 2009 May;229(1):192-215. doi: 10.1111/j.1600-065X.2009.00765.x. Review.

PMID:
19426223
3.

T-cell intrinsic effects of GITR and 4-1BB during viral infection and cancer immunotherapy.

Snell LM, Lin GH, McPherson AJ, Moraes TJ, Watts TH.

Immunol Rev. 2011 Nov;244(1):197-217. doi: 10.1111/j.1600-065X.2011.01063.x. Review. Erratum in: Immunol Rev. 2012 Jan;245(1):265.

PMID:
22017440
4.

Immunotherapy of cancer with 4-1BB.

Vinay DS, Kwon BS.

Mol Cancer Ther. 2012 May;11(5):1062-70. doi: 10.1158/1535-7163.MCT-11-0677. Epub 2012 Apr 24. Review.

5.

Role of 4-1BB:4-1BB ligand in cancer immunotherapy.

Cheuk AT, Mufti GJ, Guinn BA.

Cancer Gene Ther. 2004 Mar;11(3):215-26. Review.

PMID:
14671675
6.

Role of 4-1BB in immune responses.

Vinay DS, Kwon BS.

Semin Immunol. 1998 Dec;10(6):481-9. Review.

PMID:
9826581
7.

SA-4-1BBL as a novel adjuvant for the development of therapeutic cancer vaccines.

Sharma RK, Yolcu ES, Shirwan H.

Expert Rev Vaccines. 2014 Mar;13(3):387-98. doi: 10.1586/14760584.2014.880340. Review.

8.

4-1BB agonism: adding the accelerator to cancer immunotherapy.

Chester C, Ambulkar S, Kohrt HE.

Cancer Immunol Immunother. 2016 Oct;65(10):1243-8. doi: 10.1007/s00262-016-1829-2. Epub 2016 Mar 31. Review.

9.

The TNFRs OX40, 4-1BB, and CD40 as targets for cancer immunotherapy.

Moran AE, Kovacsovics-Bankowski M, Weinberg AD.

Curr Opin Immunol. 2013 Apr;25(2):230-7. doi: 10.1016/j.coi.2013.01.004. Epub 2013 Feb 14. Review.

10.

Immunotherapy targeting 4-1BB: mechanistic rationale, clinical results, and future strategies.

Chester C, Sanmamed MF, Wang J, Melero I.

Blood. 2018 Jan 4;131(1):49-57. doi: 10.1182/blood-2017-06-741041. Epub 2017 Nov 8. Review.

PMID:
29118009
11.

Reverse signaling through the co-stimulatory ligand, CD137L, as a critical mediator of sterile inflammation.

Park SJ, Kim HJ, Lee JS, Cho HR, Kwon B.

Mol Cells. 2012 Jun;33(6):533-7. doi: 10.1007/s10059-012-0077-3. Epub 2012 Apr 20. Review.

Supplemental Content

Support Center